ArticleAnnals of surgical oncology2021
Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer?
Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Intraoperative Radiotherapy with Balloon-Based Electronic Brachytherapy System-A Systematic Review and First Bulgarian Experience in Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2021Pooled it
- Economic and Health System Impact of Implementing the SOUND Trial Approach in Early-Stage Breast Cancer.Annals of surgical oncology · 2026Article
- De-Escalation of Axillary Surgery: A Review of Choosing Wisely Guideline Evidence.World journal of oncology · 2026Review
- Sentinel Lymph Node Biopsy in Low-Risk Breast Cancer in Patients ≥ 70 Years: How Wisely are We Choosing?Annals of surgical oncology · 2026Article
- Contemporary Nodal Management and Overall Survival of Older Patients with HR-/HER2+ Breast Cancer.Annals of surgical oncology · 2026Article
- Is sentinel lymph node frozen section analysis necessary in hormone receptor-positive, HER2-negative, clinically node-negative breast cancer patients undergoing upfront mastectomy?Frontiers in oncology · 2026Article
- A Single-Center 11-Year Experience of Surgical Management of Breast Cancer in Patients Aged 90 Years or Older.Cureus · 2025Article
- Intraoperative frozen section analysis can be omitted in early breast cancer without significantly elevating reoperation rates.BMC surgery · 2025Article
- A Prospective Study of Sentinel Node Biopsy Omission in Women Age ≥ 65 Years with ER+ Breast Cancer.Annals of surgical oncology · 2024Observational
- How to Optimize Deimplementation of Sentinel Lymph Node Biopsy?The breast journal · 2024Article
- Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study.The oncologist · 2023Article
- A novel nomogram and risk classification system for predicting lymph node metastasis of breast mucinous carcinoma: A SEER-based study.Cancer medicine · 2022Article
- The Influence of Screening Mammography Cessation and Resumption on Breast Cancer Presentation and Treatment: A Multi-Hospital Health System Experience During the Early COVID-19 Pandemic.European journal of breast health · 2022Article
- Long-term survival in elderly women receiving chemotherapy for non-metastatic breast cancer: a population-based analysis.Breast cancer research and treatment · 2022Article
- Omission of Axillary Staging and Survival in Elderly Women With Early Stage Breast Cancer: A Population-Based Cohort Study.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2022Article
- Omitting SLNB in Breast Cancer: Is a Nomogram the Answer?Annals of surgical oncology · 2022Article
- Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects.Clinical interventions in aging · 2022Review
- Omitting Sentinel Lymph Node Biopsy in Elderly Patients: A Lost Opportunity?Annals of surgical oncology · 2021Article
- Impact of Sentinel Lymph Node Biopsy on Treatment Decision and Survival in Patients Aged ≥70 Years with Breast Cancer: A Retrospective Study.Technology in cancer research & treatmentArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Society of Surgical Oncology's Choosing Wisely MATERIALS AND
methodsA single-institution retrospective review of consecutive cN0 women ≥ 70 years of age who received SLNB was performed. We collected clinicopathologic characteristics and treatment data. Patients were compared according to SLN status with subset analysis of HR-positive patients. Outcomes were analyzed using the Kaplan-Meier method and univariable analysis, and were compared using log-rank tests.
resultsOf 500 patients, 345 (69%) were SLN-negative. Median age was 74 years (range 70-96). Most tumors were T1 (72%), N0 (69%), invasive ductal (77%), without lymphovascular invasion (88%), estrogen receptor-positive (88%) and progesterone receptor-positive (75%), and human epidermal growth factor receptor 2 (HER2)-negative (88%) treated with lumpectomy (71%). Median number of SLNs obtained was 2 (range 0-12) and median number of positive SLNs was 0 (range 0-8). Characteristics of the HR-positive subset were similar. In both the overall cohort and the HR-positive subset, SLN status significantly affected the use of adjuvant chemotherapy, although no significant effect on recurrence was observed. SLN-negative patients had better overall survival and less distant recurrence (both p < 0.0001). Adjuvant hormone therapy significantly improved overall survival.
conclusionsSLNB can be safely omitted in elderly patients with T1, HR-positive, invasive ductal carcinoma tumors, but may still provide important information affecting treatment. Patients who are candidates for adjuvant systemic chemotherapy should still be considered for SLNB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.